well the 40 papers on paper are worth a little under 2/10ths of a penny each. As far as "looking forward" to "conclusively demonstrating it in our upcoming, Phase 3.....trial ....BETonMACE2"

believe we seen this same or similar statement years ago .... 

"near future" "soon" "imminent" blah blah blah - put up or shut up please.

"The depth and breadth of our knowledge of apabetalone is on full display in the forty scientific articles that we have published to date," said Donald McCaffrey, President and CEO at Resverlogix. "We firmly believe that apabetalone will help chronic disease patients, we have published an extraordinary amount of evidence that supports our belief, and we are looking forward to conclusively demonstrating it in our upcoming, Phase 3, cardiovascular disease trial, BETonMACE2."